
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Metal Mining · market cap $4.3B · as of 2026-06-29
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Lebrikizumab | Phase 3 | Atopic Dermatitis |
| Experimental: LAS 41004 dosage 1 | Phase 2 | Psoriasis |
| Experimental Tazarotene Gel | Phase 2 | Nail Psoriasis |
| LAD603 | Phase 2 | Alopecia Areata |
| LAS41004 | Phase 2 | Psoriasis |
| LAD191 | Phase 2 | Hidradenitis Suppurativa |
| LAS189961 | Phase 2 | Tinea Pedis |
| 50 mg P005672-HCl | Phase 2 | Acne Vulgaris |
| LAS41007 o.d. | Phase 2 | Actinic Keratosis |
| LAS41007 | Phase 3 | Actinic Keratosis |
| LAS 41002 | Phase 2 | Atopic Eczema |
| Tirbanibulin | Phase 3 | Keratosis, Actinic |
| LAS41003 | Phase 2 | Eczema |
| LAS41004-IMP1 | Phase 2 | Psoriasis |
| Sarecycline | Phase 3 | Acne Vulgaris |
| LAS 41004 | Phase 2 | Psoriasis |
| KX2-391 Ointment 1% | Phase 3 | Actinic Keratosis |
| 50 mg of KX2-391 Ointment 1% | Phase 2 | Actinic Keratosis |
| Tirbanibulin ointment 1% | Phase 3 | Keratosis, Actinic |
| LAS106521 | Phase 3 | Actinic Keratosis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.